FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Denning

Research Profile

Chemicals & Drugs

Disorders

Procedures

Microbial Sensitivity Tests

Living Beings

Physiology

Co-author Network

Publications

TOP 3
C G Baxter; David W Denning; A M Jones; C B Moore; A Todd; M D Richardson
Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis.
Paul Bowyer; Michael Bromley; Michael Anderson; Mike Birch; Juan Mosquera; David W Denning
Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.
Livingstone Chishimba; John Cooley; Robert M Niven; David W Denning
Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Denning (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: C G Baxter; David W Denning; A M Jones; C B Moore; A Todd; M D Richardson
Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2013;19(4):E197-204.
2012: Paul Bowyer; Michael Bromley; Michael Anderson; Mike Birch; Juan Mosquera; David W Denning
Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.
FEMS microbiology letters 2012;332(1):10-9.
2012: Livingstone Chishimba; John Cooley; Robert M Niven; David W Denning
Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
The Journal of asthma : official journal of the Association for the Care of Asthma 2012;49(4):423-33.
2011: Paul Bowyer; David W Denning; Caroline B Moore; Riina Rautemaa; Malcolm D Richardson
Azole antifungal resistance today: focus on Aspergillus.
Current infectious disease reports 2011;13(6):485-91.
2011: David W Denning; David S Perlin
Azole resistance in Aspergillus: a growing public health menace.
Future microbiology 2011;6(11):1229-32.
2011: Ahmed M Albarrag; Michael J Anderson; Susan J Howard; Geoff D Robson; Dominique Sanglard; Peter A Warn; David W Denning
Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter.
Antimicrobial agents and chemotherapy 2011;55(11):5113-21.
2011: Susan J Howard; Janos Varga; Paul Bowyer; Elizabeth Harrison; David W Denning
Cryptic species and azole resistance in the Aspergillus niger complex.
Antimicrobial agents and chemotherapy 2011;55(10):4802-9.
2011: Caroline G Baxter; Timothy W Felton; Andrew Marshall; Mark Roberts; David W Denning
Peripheral neuropathy in patients on long-term triazole antifungal therapy.
The Journal of antimicrobial chemotherapy 2011;66(9):2136-9.
2011: Caroline G Baxter; Paul Bishop; Kweku Baiden-Amissah; Su Enn Low; David W Denning
Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography.
Thorax 2011;66(7):638-40.
2011: David W Denning; Steven Park; Cornelia Lass-Florl; Marcin G Fraczek; Marie Kirwan; Robin Gore; Jaclyn Smith; Ahmed Bueid; Caroline B Moore; Paul Bowyer; David S Perlin
High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52(9):1123-9.
2011: Philippe M Hauser; Jacques Bille; Cornelia Lass-Flörl; Christian Geltner; Marta Feldmesser; Michael H Levi; Hitesh Patel; Victoria Muggia; Barbara Alexander; Martin Hughes; Sarah A Follett; Xiaohui Cui; Flora Leung; Gillian Morgan; Adrian Moody; David S Perlin; David W Denning
Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay.
Journal of clinical microbiology 2011;49(5):1872-8.
2011: J L Slater; L Gregson; David W Denning; Peter A Warn
Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2011;49 Suppl 1():S107-13.
2011: N L Smith; David W Denning
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2011;37(4):865-72.
2011: Rangaprasad L Karadi; David Gow; Mark Kellett; David W Denning; Ronan B O'Driscoll
Itraconazole associated quadriparesis and edema: a case report.
Journal of medical case reports 2011;5():140.
2010: Ahmed Bueid; Susan J Howard; Caroline B Moore; Malcolm D Richardson; Elizabeth Harrison; Paul Bowyer; David W Denning
Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.
The Journal of antimicrobial chemotherapy 2010;65(10):2116-8.
2010: Timothy W Felton; Victoria Plested; Anna Walsham; Paul Dark; Ronan O'Driscoll; David W Denning
A 27-year-old woman with acute, severe asthma who developed respiratory failure.
Chest 2010;137(3):724-7.
2010: Jodi M Lestner; David W Denning
Tremor: a newly described adverse event with long-term itraconazole therapy.
Journal of neurology, neurosurgery, and psychiatry 2010;81(3):327-9.
2010: Peter A Warn; Andrew Sharp; Graham Morrissey; David W Denning
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
International journal of antimicrobial agents 2010;35(2):146-51.
2009: Alessandro C Pasqualotto; Georgina Powell; Robert Niven; David W Denning
The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis.
Respirology (Carlton, Vic.) 2009;14(8):1121-7.
2009: I Hassan; G Powell; M Sidhu; W M Hart; David W Denning
Excess mortality, length of stay and cost attributable to candidaemia.
The Journal of infection 2009;59(5):360-5.
2009: Peter A Warn; Andrew Sharp; Arvind Parmar; Jayesh Majithiya; David W Denning; William W Hope
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.
Antimicrobial agents and chemotherapy 2009;53(8):3453-61.
2009: Rifat Rashid; David W Denning
Invasive pulmonary aspergillosis 10 years post bone marrow transplantation: a case report.
Journal of medical case reports 2009;3():26.
2008: William W Hope; Eliane M Billaud; Jodie Lestner; David W Denning
Therapeutic drug monitoring for triazoles.
Current opinion in infectious diseases 2008;21(6):580-6.
2008: Alessandro Comarú Pasqualotto; David W Denning
An aspergilloma caused by Aspergillus flavus.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2008;46(3):275-8.
2008: THOMAS WALSH; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne H van Burik; John R Wingard; Thomas Patterson
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(3):327-60.
2008: Alessandro Comarú Pasqualotto; David W Denning
New and emerging treatments for fungal infections.
The Journal of antimicrobial chemotherapy 2008;61 Suppl 1():i19-30.
2007: William W Hope; Peter A Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; THOMAS WALSH; David W Denning; George L Drusano
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Antimicrobial agents and chemotherapy 2007;51(10):3760-2.
2007: Alessandro Comarú Pasqualotto; David W Denning
Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance.
International journal of antimicrobial agents 2007;30(1):93-4.
2007: Maiken Cavling Arendrup; David W Denning; Michael A Pfaller; D J Diekema; J H Rex
Does one voriconazole breakpoint suit all Candida species?
Journal of clinical microbiology 2007;45(6):2093; author reply 2094.
2007: Alessandro Comarú Pasqualotto; Susan J Howard; Caroline B Moore; David W Denning
Flucytosine therapeutic monitoring: 15 years experience from the UK.
The Journal of antimicrobial chemotherapy 2007;59(4):791-3.
2007: Paul Bowyer; David W Denning
Genomic analysis of allergen genes in Aspergillus spp: the relevance of genomics to everyday research.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2007;45(1):17-26.
2007: Alessandro Comarú Pasqualotto; David W Denning; Michael J Anderson
A cautionary tale: Lack of consistency in allele sizes between two laboratories for a published multilocus microsatellite typing system.
Journal of clinical microbiology 2007;45(2):522-8.
2007: Mudit Vaid; Savneet Kaur; Helen Sambatakou; Taruna Madan; David W Denning; P Usha Sarma
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2007;45(2):183-6.
2007: Juan L Rodriguez-Tudela; J Peter Donnelly; Michael A Pfaller; Erja Chryssantou; Peter A Warn; David W Denning; Ana Espinel-Ingroff; Francesco Barchiesi; Manuel Cuenca Estrella
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).
Journal of clinical microbiology 2007;45(1):109-11.
2007: William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; THOMAS WALSH; David W Denning; Peter A Warn
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Antimicrobial agents and chemotherapy 2007;51(1):285-95.
2006: Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.
The Journal of antimicrobial chemotherapy 2006;58(6):1198-207.
2006: Susan J Howard; Ian Webster; Caroline B Moore; Rebecca E Gardiner; Steven Park; David Perlin; David W Denning
Multi-azole resistance in Aspergillus fumigatus.
International journal of antimicrobial agents 2006;28(5):450-3.
2006: Alessandro Comarú Pasqualotto; David W Denning
Post-operative aspergillosis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(11):1060-76.
2006: William W Hope; Peter A Warn; Andrew Sharp; Susan Howard; Miki Kasai; Arnold Louie; THOMAS WALSH; George L Drusano; David W Denning
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Antimicrobial agents and chemotherapy 2006;50(11):3680-8.
2006: David W Denning; Kieren Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas Patterson
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
The Journal of infection 2006;53(5):337-49.
2006: Helen Sambatakou; V Pravica; Ian Hutchinson; David W Denning
Cytokine profiling of pulmonary aspergillosis.
International journal of immunogenetics 2006;33(4):297-302.
2006: Helen Sambatakou; Bertrand Dupont; Hartmut Lode; David W Denning
Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
The American journal of medicine 2006;119(6):527.e17-24.
2006: Lakshmi R Jain; David W Denning
The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.
The Journal of infection 2006;52(5):e133-7.
2006: E C Hamer; Caroline B Moore; David W Denning
Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(2):181-4.
2006: Paul Bowyer; Marcin Fraczek; David W Denning
Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues.
BMC genomics 2006;7():251.
2006: Maiken Cavling Arendrup; B Ronan O'Driscoll; Eskild Petersen; David W Denning
Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings.
Scandinavian journal of infectious diseases 2006;38(10):945-9.
2006: Ashley Woodcock; N Steel; Caroline B Moore; Susan J Howard; Adnan Custovic; David W Denning
Fungal contamination of bedding.
Allergy 2006;61(1):140-2.
2006: Peter A Warn; Andrew Sharp; David W Denning
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
The Journal of antimicrobial chemotherapy 2006;57(1):135-8.
2005: William W Hope; THOMAS WALSH; David W Denning
Laboratory diagnosis of invasive aspergillosis.
The Lancet infectious diseases 2005;5(10):609-22.
2005: Peter A Warn; Andrew Sharp; Graham Morrissey; David W Denning
Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
The Journal of antimicrobial chemotherapy 2005;56(3):590-3.
2005: William W Hope; Peter A Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; David W Denning; George L Drusano
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
The Journal of infectious diseases 2005;192(4):673-80.
2005: Derek Paisley; Geoff Robson; David W Denning
Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2005;43(5):397-401.
2005: William W Hope; THOMAS WALSH; David W Denning
The invasive and saprophytic syndromes due to Aspergillus spp.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2005;43 Suppl 1():S207-38.
2005: Andrew R Dodgson; Claude Pujol; Michael A Pfaller; David W Denning; David Soll
Evidence for recombination in Candida glabrata.
Fungal genetics and biology : FG & B 2005;42(3):233-43.
2005: B Ronan O'Driscoll; Linda C Hopkinson; David W Denning
Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions.
BMC pulmonary medicine 2005;5():4.
2004: Brian G Keevil; Sheila Newman; Stephen Lockhart; Susan J Howard; Caroline B Moore; David W Denning
Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry.
Therapeutic drug monitoring 2004;26(6):650-7.
2004: William W Hope; Lydia Tabernero; David W Denning; Michael J Anderson
Molecular mechanisms of primary resistance to flucytosine in Candida albicans.
Antimicrobial agents and chemotherapy 2004;48(11):4377-86.
2004: Aileen E Boyd; Simon Modi; Susan J Howard; Caroline B Moore; Brian G Keevil; David W Denning
Adverse reactions to voriconazole.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(8):1241-4.
2004: William W Hope; Alan Padwell; Malcolm Guiver; David W Denning
Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens.
The Journal of infection 2004;49(2):136-40.
2004: Peter A Warn; Andrew Sharp; J Guinea; David W Denning
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.
The Journal of antimicrobial chemotherapy 2004;53(5):743-9.
2004: Mike Birch; David W Denning; Geoff Robson
Comparison of extracellular phospholipase activities in clinical and environmental Aspergillus fumigatus isolates.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2004;42(1):81-6.
2004: JE Mabey; Michael J Anderson; P F Giles; C J Miller; Teresa K Attwood; Norman W Paton; Erich Bornberg-Bauer; Geoff Robson; Stephen G Oliver; David W Denning
CADRE: the Central Aspergillus Data REpository.
Nucleic acids research 2004;32(Database issue):D401-5.
2003: Andrew R Dodgson; Claude Pujol; David W Denning; David Soll; Andrew J Fox
Multilocus sequence typing of Candida glabrata reveals geographically enriched clades.
Journal of clinical microbiology 2003;41(12):5709-17.
2003: David W Denning
Echinocandin antifungal drugs.
Lancet 2003;362(9390):1142-51.
2003: David W Denning; Kostantinos Riniotis; Richard Dobrashian; Helen Sambatakou
Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37 Suppl 3():S265-80.
2003: Manuel Cuenca Estrella; C B Moore; Francesco Barchiesi; J Bille; E Chryssanthou; David W Denning; J Peter Donnelly; F Dromer; B Dupont; J H Rex; MALCOLM RICHARDSON; B Sancak; P E Verweij; Juan Luis Rodríguez Tudela
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(6):467-74.
2003: Peter A Warn; M W Brampton; Andrew Sharp; Graham Morrissey; N Steel; David W Denning; T Priest
Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections.
Laboratory animals 2003;37(2):126-31.
2003: David W Denning; Christopher Kibbler; Rosemary A Barnes
British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.
The Lancet infectious diseases 2003;3(4):230-40.
2003: Peter A Warn; Graham Morrissey; J Morrissey; David W Denning
Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
The Journal of antimicrobial chemotherapy 2003;51(4):913-9.
2003: Caroline B Moore; Caroline M Walls; David W Denning
Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine.
The Journal of antimicrobial chemotherapy 2003;51(2):297-304.
2002: Peter A Warn; Andrew Sharp; Graham Morrissey; David W Denning
In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.
The Journal of antimicrobial chemotherapy 2002;50(6):1071-4.
2002: Juan Mosquera; Andrew Sharp; Caroline B Moore; Peter A Warn; David W Denning
In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
The Journal of antimicrobial chemotherapy 2002;50(2):189-94.
2002: John W Slaven; Michael J Anderson; Dominique Sanglard; Graham K Dixon; Jacques Bille; Ian S D Roberts; David W Denning
Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate.
Fungal genetics and biology : FG & B 2002;36(3):199-206.
2002: David W Denning
Echinocandins: a new class of antifungal.
The Journal of antimicrobial chemotherapy 2002;49(6):889-91.
2002: David W Denning; Michael J Anderson; Geoffrey Turner; Jean-Paul Latgé; Joan W Bennett
Sequencing the Aspergillus fumigatus genome.
The Lancet infectious diseases 2002;2(4):251-3.
2002: David W Denning; Patricia Ribaud; Noël Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(5):563-71.
2002: Juan Mosquera; David W Denning
Azole cross-resistance in Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 2002;46(2):556-7.
2002: S Ascioglu; John H Rex; Ben E de Pauw; JOHN BENNETT; J Bille; F Crokaert; David W Denning; J Peter Donnelly; John Edwards; Z Erjavec; D Fiere; Olivier Lortholary; Johan Maertens; Jacques Meis; Thomas Patterson; J Ritter; Dominik Selleslag; P M Shah; D A Stevens; THOMAS WALSH
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(1):7-14.
2001: David W Denning; Christopher E M Griffiths
Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
Clinical and experimental dermatology 2001;26(8):648-53.
2001: Juan Mosquera; Peter A Warn; Juan L Rodriguez-Tudela; David W Denning
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.
The Journal of antimicrobial chemotherapy 2001;48(4):583-6.
2001: DJ Crosdale; Kay V Poulton; W E R Ollier; Wendy Thomson; David W Denning
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis.
The Journal of infectious diseases 2001;184(5):653-6.
2001: Caroline B Moore; Caroline M Walls; David W Denning
In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B.
Antimicrobial agents and chemotherapy 2001;45(6):1882-5.
2001: Juan Mosquera; Peter A Warn; J Morrissey; Caroline B Moore; Cristina Gil-Lamaignere; David W Denning
Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.
Antimicrobial agents and chemotherapy 2001;45(5):1456-62.
2001: David W Denning
Chronic forms of pulmonary aspergillosis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7 Suppl 2():25-31.
2001: Caroline B Moore; KL Oakley; David W Denning
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7(1):11-6.
2000: Caroline B Moore; N Sayers; J Mosquera; J Slaven; David W Denning
Antifungal drug resistance in Aspergillus.
The Journal of infection 2000;41(3):203-20.
2000: Jayne L Brookman; David W Denning
Molecular genetics in Aspergillus fumigatus.
Current opinion in microbiology 2000;3(5):468-74.
2000: Peter A Warn; J Morrissey; Caroline B Moore; David W Denning
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis.
Antimicrobial agents and chemotherapy 2000;44(10):2664-71.
2000: A I Thuraisingam; David W Denning
Candida glabrata oesophagitis in a patient without HIV infection.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2000;19(7):561-2.
2000: David W Denning
Early diagnosis of invasive aspergillosis.
Lancet 2000;355(9202):423-4.
2000: Caroline B Moore; Caroline M Walls; David W Denning
In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.
Antimicrobial agents and chemotherapy 2000;44(2):441-3.
2000: Elizabeth M Johnson; KL Oakley; SA Radford; Caroline B Moore; Peter A Warn; DW Warnock; David W Denning
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.
The Journal of antimicrobial chemotherapy 2000;45(1):85-93.
2000: Olivier Lortholary; S Ascioglu; P Moreau; Raoul Herbrecht; A Marinus; P Casassus; Ben E de Pauw; David W Denning
Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30(1):41-6.
1999: M Birch; David W Denning
Molecular typing of Aspergillus terreus by random amplification of polymorphic DNA.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1999;18(11):838-41.
1999: David W Denning; Peter A Warn
Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Antimicrobial agents and chemotherapy 1999;43(11):2592-9.
1999: KL Oakley; Caroline B Moore; David W Denning
Activity of pradimicin BMS-181184 against Aspergillus spp.
International journal of antimicrobial agents 1999;12(3):267-9.
1999: KL Oakley; Caroline B Moore; David W Denning
Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.
Antimicrobial agents and chemotherapy 1999;43(5):1264-6.
1999: Olivier Lortholary; David W Denning; B Dupont
Endemic mycoses: a treatment update.
The Journal of antimicrobial chemotherapy 1999;43(3):321-31.
1999: SV Hood; S Hollis; M Percy; G Atkinson; K Williams; David W Denning
Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(3):587-96.
1999: T Takasuka; Nicola M Sayers; Michael J Anderson; Emyr W Benbow; David W Denning
Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases.
FEMS immunology and medical microbiology 1999;23(2):125-33.
1998: KL Oakley; Caroline B Moore; David W Denning
In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
Antimicrobial agents and chemotherapy 1998;42(10):2726-30.
1998: David W Denning; A Marinus; J Cohen; D Spence; Raoul Herbrecht; L Pagano; C Kibbler; V Kcrmery; F Offner; C Cordonnier; U Jehn; M Ellis; L Collette; R Sylvester
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group.
The Journal of infection 1998;37(2):173-80.
1998: Paul E Verweij; M Mensink; Antonius J M M Rijs; J Peter Donnelly; Jacques Meis; David W Denning
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
The Journal of antimicrobial chemotherapy 1998;42(3):389-92.
1998: SV Hood; J Evans; J Bond; E Wilkins; David W Denning
The treatment of oropharyngeal candidiasis in HIV-infected patients with oral amphotericin B suspension.
AIDS patient care and STDs 1998;12(8):625-7.
1998: KL Oakley; Caroline B Moore; David W Denning
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
The Journal of antimicrobial chemotherapy 1998;42(1):91-4.
1998: M Birch; David B Drucker; I Riba; S J Gaskell; David W Denning
Polar lipids of Aspergillus fumigatus, A. niger, A. nidulans, A. flavus and A. terreus.
Medical mycology : official publication of the International Society for Human and Animal Mycology 1998;36(3):127-34.
1998: David W Denning
Invasive aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(4):781-803; quiz 804-5.
1998: Paul E Verweij; KL Oakley; J Morrissey; Graham Morrissey; David W Denning
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Antimicrobial agents and chemotherapy 1998;42(4):873-8.
1998: SV Hood; A Bonington; J Evans; David W Denning
Reduction in oropharyngeal candidiasis following introduction of protease inhibitors.
AIDS (London, England) 1998;12(4):447-8.
1998: Paul E Verweij; D Poulain; T Obayashi; Thomas Patterson; David W Denning; J Ponton
Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections.
Medical mycology : official publication of the International Society for Human and Animal Mycology 1998;36 Suppl 1():146-55.
1998: T Takasuka; G G Baily; M Birch; M J Anderson; D Law; David W Denning
Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient.
The Journal of infection 1998;36(1):57-62.
1997: David W Denning
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.
The Journal of antimicrobial chemotherapy 1997;40(5):611-4.
1997: D Law; Caroline B Moore; David W Denning
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
Antimicrobial agents and chemotherapy 1997;41(10):2310-1.
1997: David W Denning; SA Radford; KL Oakley; L Hall; Elizabeth M Johnson; DW Warnock
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.
The Journal of antimicrobial chemotherapy 1997;40(3):401-14.
1997: SV Hood; Caroline B Moore; David W Denning
Neurospora sitophila pulmonary infection in a patient with AIDS.
AIDS patient care and STDs 1997;11(4):223-6.
1997: D Law; Caroline B Moore; David W Denning
Amphotericin B resistance testing of Candida spp.: a comparison of methods.
The Journal of antimicrobial chemotherapy 1997;40(1):109-12.
1997: G G Baily; Caroline B Moore; S M Essayag; S de Wit; James Burnie; David W Denning
Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(1):161-3.
1997: KL Oakley; Graham Morrissey; David W Denning
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 1997;41(7):1504-7.
1997: David W Denning; E G Evans; C C Kibbler; MALCOLM RICHARDSON; M M Roberts; T R Rogers; DW Warnock; R E Warren
Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1997;16(6):424-36.
1997: K Venkateswarlu; David W Denning; Steven L Kelly
In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei.
The Journal of antimicrobial chemotherapy 1997;39(6):731-6.
1997: SV Hood; Caroline B Moore; John Cheesbrough; A Mene; David W Denning
Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine.
The British journal of dermatology 1997;136(6):953-6.
1997: David W Denning; K Venkateswarlu; KL Oakley; M J Anderson; Nigel J Manning; D A Stevens; DW Warnock; Steven L Kelly
Itraconazole resistance in Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 1997;41(6):1364-8.
1997: KL Oakley; Caroline B Moore; David W Denning
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.
Antimicrobial agents and chemotherapy 1997;41(5):1124-6.
1997: David W Denning; G G Baily; SV Hood
Azole resistance in Candida.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1997;16(4):261-80.
1997: S Nho; M J Anderson; Caroline B Moore; David W Denning
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains.
Journal of clinical microbiology 1997;35(4):1036-9.
1997: M Birch; David B Drucker; V Boote; David W Denning
Prevalence of phthioic acid in Aspergillus species.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1997;35(2):143-5.
1997: K Venkateswarlu; David W Denning; Steven L Kelly
Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1997;35(1):19-25.
1996: D Law; P R Sisson; Roger Freeman; David W Denning
Characterization of Aspergillus isolates by pyrolysis mass spectrometry.
Mycoses 1996;39(11-12):433-6.
1996: SV Hood; Caroline B Moore; David W Denning
Isolation of Candida norvegensis from clinical specimens: four case reports.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(5):1185-7.
1996: K Venkateswarlu; David W Denning; Nigel J Manning; Steven L Kelly
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance.
Antimicrobial agents and chemotherapy 1996;40(11):2443-6.
1996: D Law; Caroline B Moore; L A Joseph; M G L Keaney; David W Denning
High incidence of antifungal drug resistance in Candida tropicalis.
International journal of antimicrobial agents 1996;7(4):241-5.
1996: Gordon L Carlson; M M Mughal; M Birch; David W Denning
Aspergillus wound infection following laparostomy.
The Journal of infection 1996;33(2):119-21.
1996: David W Denning
Therapeutic outcome in invasive aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(3):608-15.
1996: H M Wardle; D Law; David W Denning
In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.
Antimicrobial agents and chemotherapy 1996;40(9):2229-31.
1996: K Venkateswarlu; David W Denning; Nigel J Manning; Steven L Kelly
Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays.
Antimicrobial agents and chemotherapy 1996;40(6):1382-6.
1996: S Hood; David W Denning
Treatment of fungal infection in AIDS.
The Journal of antimicrobial chemotherapy 1996;37 Suppl B():71-85.
1996: Rosemary A Barnes; David W Denning; E G Evans; R J Hay; C C Kibbler; A G Prentice; MALCOLM RICHARDSON; M M Roberts; T R Rogers; D C Speller; D W Warnock; R E Warren
Fungal infections: a survey of laboratory services for diagnosis and treatment.
Communicable disease report. CDR review 1996;6(5):R69-75.
1996: M Birch; David W Denning; D Law
Rapid genotyping of Escherichia coli O157 isolates by random amplification of polymorphic DNA.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1996;15(4):297-302.
1996: M Birch; Geoff Robson; D Law; David W Denning
Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus.
Infection and immunity 1996;64(3):751-5.
1996: David W Denning
Aspergillosis: diagnosis and treatment.
International journal of antimicrobial agents 1996;6(3):161-8.
1996: G M Megson; D A Stevens; J R Hamilton; David W Denning
D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis.
Journal of clinical microbiology 1996;34(1):218-21.
1996: M J Anderson; K Gull; David W Denning
Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus.
Journal of clinical microbiology 1996;34(1):87-93.
1996: S M Essayag; G G Baily; David W Denning; J P Burnie
Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua.
International journal of systematic bacteriology 1996;46(1):35-40.
1995: T R Rogers; Rosemary A Barnes; David W Denning; E G Evans; R J Hay; A G Prentice; D C Speller; D W Warnock; R E Warren
Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy.
The Journal of antimicrobial chemotherapy 1995;36(6):899-909.
1995: K Venkateswarlu; David W Denning; Nigel J Manning; Steven L Kelly
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug.
FEMS microbiology letters 1995;131(3):337-41.
1995: David W Denning
Can we prevent azole resistance in fungi?
Lancet 1995;346(8973):454-5.
1995: David W Denning; L Hall; M Jackson; S Hollis
Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.
Antimicrobial agents and chemotherapy 1995;39(8):1809-14.
1995: M Birch; M J Anderson; David W Denning
Molecular typing of Aspergillus species.
The Journal of hospital infection 1995;30 Suppl():339-51.
1995: H M Wardle; D Law; Caroline B Moore; C Mason; David W Denning
In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp.
Antimicrobial agents and chemotherapy 1995;39(4):868-71.
1995: R Duthie; David W Denning
Aspergillus fungemia: report of two cases and review.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20(3):598-605.
1995: M Birch; N Nolard; Gillian Shankland; David W Denning
DNA typing of epidemiologically-related isolates of Aspergillus fumigatus.
Epidemiology and infection 1995;114(1):161-8.
1995: Saye H Khoo; David W Denning
Cure of chronic invasive sinus aspergillosis with oral saperconazole.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1995;33(1):63-6.
1995: David W Denning
Issues in the management of invasive aspergillosis.
Annales de médecine interne 1995;146(2):106-10.
1994: L A Hall; David W Denning
Oxygen requirements of Aspergillus species.
Journal of medical microbiology 1994;41(5):311-5.
1994: D Law; Caroline B Moore; H M Wardle; L A Ganguli; M G L Keaney; David W Denning
High prevalence of antifungal resistance in Candida spp. from patients with AIDS.
The Journal of antimicrobial chemotherapy 1994;34(5):659-68.
1994: T T Ng; Geoff Robson; David W Denning
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis.
Microbiology (Reading, England) 1994;140 ( Pt 9)():2475-9.
1994: Saye H Khoo; David W Denning
Invasive aspergillosis in patients with AIDS.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;19 Suppl 1():S41-8.
1994: D Law; Caroline B Moore; David W Denning
Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards.
Antimicrobial agents and chemotherapy 1994;38(7):1561-6.
1994: G G Baily; F M Perry; David W Denning; BK Mandal
Fluconazole-resistant candidosis in an HIV cohort.
AIDS (London, England) 1994;8(6):787-92.
1994: David W Denning
Treatment of invasive aspergillosis.
The Journal of infection 1994;28 Suppl 1():25-33.
1994: D Law; A A Hamour; David W K Acheson; H Panigrahi; L A Ganguli; David W Denning
Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples.
Journal of medical microbiology 1994;40(4):241-5.
1994: S H Khoo; J Bond; David W Denning
Administering amphotericin B--a practical approach.
The Journal of antimicrobial chemotherapy 1994;33(2):203-13.
1993: Caroline B Moore; D Law; David W Denning
In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp.
The Journal of antimicrobial chemotherapy 1993;32(6):831-6.
1993: I S Fraser; David W Denning
Empiric amphotericin B therapy: the need for a reappraisal.
Blood reviews 1993;7(4):208-14.
1993: T T Ng; David W Denning
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach.
The Journal of infection 1993;26(2):117-25.
1992: David W Denning; P N Ward; L E Fenelon; E W Benbow
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis.
Infection and immunity 1992;60(12):5153-6.
1992: Saye H Khoo; G Bailey; Edmund G L Wilkins; David W Denning
Time to finish with "AIDS"?
Lancet 1992;339(8804):1298.
1991: David W Denning
Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host.
The Journal of antimicrobial chemotherapy 1991;28 Suppl B():1-16.